Updating results

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

In development [GID-TA10328] Expected publication date: TBC

Technology appraisal guidance In development

Galcanezumab for preventing migraine [ID1372]

In development [GID-TA10454] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Technology appraisal guidance In development

Mental health community settings

In development [GID-SGWAVE0702] Expected publication date: TBC

Safe staffing guideline In development

Cardiac transplantation (rejection) - everolimus [ID114]

In development [GID-TAG232] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (primary-progressive) - fingolimod [ID62]

In development [GID-TAG221] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - ximelagatran [ID376]

In development [GID-TAG377] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264

In development [GID-TA10365] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Eltrombopag for untreated severe aplastic anaemia ID1198

In development [GID-TA10284] Expected publication date: TBC

Technology appraisal guidance In development

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed

Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

In development [GID-TA10338] Expected publication date: TBC

Technology appraisal guidance In development

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413

In development [GID-TA10329] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Technology appraisal guidance In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Technology appraisal guidance Proposed

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Technology appraisal guidance Proposed

Moxetumomab pasudotox for hairy-cell leukaemia [ID1142]

In development [GID-TA10288] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: TBC

Technology appraisal guidance In development

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Technology appraisal guidance In development

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

Proposed [GID-TA10387] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 August 2020

Technology appraisal guidance In development

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

KTE-X19 for treating relapsed or refractory mantle cell lymphoma ID1313

In development [GID-TA10312] Expected publication date: 06 December 0021

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: TBC

Technology appraisal guidance Proposed

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Technology appraisal guidance Proposed

Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331

In development [GID-TA10318] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: TBC

Technology appraisal guidance In development

Luspatercept for treating beta-thalassaemia ID1554

Proposed [GID-TA10506] Expected publication date: 16 September 2020

Technology appraisal guidance Proposed

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Eflornithine with sulindac for treating familial adenomatous polyposis ID1543

Proposed [GID-TA10536] Expected publication date: TBC

Technology appraisal guidance Proposed

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

Proposed [GID-TA10544] Expected publication date: TBC

Technology appraisal guidance Proposed

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

Proposed [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance Proposed

Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Technology appraisal guidance In development